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Early genetic research focused on 
identifying single genes responsible for 
specifi c familial disorders. However, 
radical technological advancements such as 
high throughput testing and genome-wide 
scanning techniques have made it possible 
to examine complex conditions infl uenced 
by multiple genes and environmental 
factors to determine population 
susceptibility. Genetic epidemiology 
studies the distribution of genetic traits and 
variation within families and populations, 
risk factors associated with the frequency 
of genetic traits, and the role of genetic 
factors in disease aetiology (Khoury, Beaty 
& Cohen, 19931). This enables the impact 
of a specifi c genetic variation on disease 
risk in an individual or in a population 
to be estimated (Kaprio, 20002). As the 
contribution of a single gene variant to disease 
can be relatively small, it is important to understand not 
only the contribution of other genetic factors but how 
these interact with environmental 
factors to modulate disease risk. 
In New Zealand, Mäori 
communities have expressed 
interest in genetic aspects of health 
concerns affecting whanau, hapu 
and iwi. Current genetic studies 
involving Mäori are focused 
on a range of issues, including 
stomach cancer, heart disease, 
diabetes, gout and nicotine 
metabolism. The association of 
genetic susceptibility to disease 
with ethnicity is problematic 
for population genetic research, 
with the potential for community 
disruption, stigmatisation, 
stereotyping or undermining either through research 
processes or outcomes (Hausman, 20083). Care needs to 
be taken to avoid such harm through use of incorrect 
terms, for example ‘Mäori genes’.
The benefi ts of genomic research are in the early stages 
of being realised. Pharmacogenomic applications are 
nearing fruition, with testing for genetic variation 
potentially enabling more specialised and effective 
drug therapy. In the absence of genetic interventions 
however, there remains a reliance 
on prevention strategies to 
reduce risk, with many genome 
study fi ndings reinforcing 
rather than building on existing 
health promotion messages. This 
highlights a key challenge for 
population genetic research; to 
communicate more fully not only 
the potential risks of participation, 
but realistic timeframes and 
expectations for the generation 
of additional or novel benefi ts. 
Continuing progress will 
require ongoing dialogue and 
understanding, in the context 
of robust science-community 
partnerships.
1 M.J. Khoury, T.H. Beaty & B.H. Cohen, Fundamentals of Genetic 
Epidemiology, Oxford: Oxford University Press, 1993.
2 Jaakko Kaprio, ‘Science, Medicine and the Future, Genetic 
Epidemiology’, BMJ 2000;320:1257-1259.
3 Daniel Hausman, ‘Protecting Groups from Genetic Research’, 
Bioethics 2008; 22:3, 157–165.
(Photograph courtesy of Te Waihono a Kupe kapa haka group)
*“Everything we do is about 
a relationship and beyond the 
individual but to that collective,
for genetic researchers to think 
about the implications not just 
for the individual but for the 
tribe, the iwi, the hapu, all 
those levels.”
 – Professor Karina Walters
(Choctaw Nation, USA)
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